BiotechTube
BioSputnik

BioSputnik

Boston, United States· Est.
biosputnik.org
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioSputnik is a privately held, pre-revenue biotech and consulting hybrid founded in 2017. The company pursues a dual strategy: conducting internal R&D on early-stage therapies while generating expertise and potential revenue through external consulting in medical affairs, clinical development, and regulatory science. With a small, academically-focused team, the company appears to be in a foundational, resource-constrained stage, leveraging its leadership's industry experience to build its proprietary pipeline and service offerings.

OncologyPulmonary diseases

Technology Platform

Integrated expertise model combining clinical/regulatory knowledge, data science/bioinformatics, and traditional in vitro/in vivo experimental validation.

Opportunities

The consulting arm provides a pathway to generate non-dilutive revenue and deep industry insights while funding internal R&D.
Leveraging AI/ML in therapeutic discovery positions the company in a high-growth sector with the potential to identify novel, valuable drug candidates more efficiently.
The team's experience in oncology and pulmonary diseases offers entry into large, high-need therapeutic markets.

Risk Factors

Extreme resource constraints and lack of disclosed funding threaten the ability to advance any pipeline.
The complete absence of public pipeline details creates high uncertainty regarding the company's core asset value.
The hybrid business model risks diluting focus, with consulting potentially insufficient to fund meaningful R&D.

Competitive Landscape

In consulting, BioSputnik competes with large, established CROs and niche specialist firms. In AI-driven drug discovery, it faces intense competition from well-funded pure-play AI biotechs (e.g., Recursion, Exscientia) and internal initiatives at large pharma. Its small size and stealth mode place it at a significant scale disadvantage.

More companies in Digital Health & Biotech SaaS →More companies in United States →